drugset
drugset / Trial / NCT00866242

Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb

NCT00866242 ↗

Phase 2 Terminated 20 enrolled University of Maryland, Baltimore PATH · collab
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.

Timeline

Start
2010-01
Primary completion
2010-02
Completion
2010-02

Outcome

Outcome not reported

Stopped: “Reactogenicity met study halting criteria”

Drugs

EvaluationDrugModalityDoseRoute
Subject CVD 1208S Vaccine — Oral

Indications

shigellosis